Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
WEGOVY semaglutide 7.2 mg/.75mL Injection, Solution, 4 syringes — NDC 0169-4572-14 (Billing 00169-4572-14)
by Novo Nordisk Pharmaceutical Industries, LP · 4 SYRINGE, PLASTIC in 1 CARTON / .75 mL in 1 SYRINGE, PLASTIC
This is a package of 4 syringes of WEGOVY semaglutide 7.2 mg/.75mL Injection, Solution from Novo Nordisk Pharmaceutical Industries, LP, marketed since Jun 2021 and currently FDA-listed; retail pharmacies pay about $434.95 per mL (NADAC). It is this product's only package size.
NDC 00169-4572-14
🏷️ FDA NDC (as labeled)
0169-4572-14
billing pads the labeler segment with a zero
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 0169-4572-14 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 0169 labeler · 4572 product · 14 package
- Package marketed since
- Mar 19, 2026
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 0169457214 0
- FDA record last changed
- Oct 8, 2026
🚨
Active recall for this product.
Class II · Dec 19, 2025 — Presence of Particulate Matter: Hair was found in a prefilled syringe (Novo Nordisk Inc.) · FDA recall D-0244-2026
Lots / codes: Lot #: RZFHD52, RZFHW93; Exp Date 10/31/2026 · reported Jan 7, 2026
Class II · Dec 19, 2025 — Presence of Particulate Matter: Hair was found in a prefilled syringe (Novo Nordisk Inc.) · FDA recall D-0245-2026
Lots / codes: Lot #: RZFYK06, RZFYA53; Exp Date 3/31/2027 · reported Jan 7, 2026
Class II · Apr 9, 2025 — Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released. (Cardinal Health Inc.) · FDA recall D-0393-2025
Lots / codes: Lot PZFDE06, Exp 08/31/2025 · reported May 7, 2025
Check your lot/expiration against the official notice — look up the recall number in the FDA recall database ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
0169-4572-14
Product NDC
0169-4572
11-digit billing NDC
00169457214
NCPDP billing unit
ML — per mL (volume)
Application #
NDA215256
SPL Set ID
f7b108b9-f276-4e32-84e7-e828ba145da5
Established class (EPC)
GLP-1 Receptor Agonist
Mechanism of action
Glucagon-like Peptide-1 (GLP-1) Agonists
Chemical class
Glucagon-Like Peptide 1
DEA schedule
Non-controlled
Marketing category
NDA
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2021-06-05
Route
SUBCUTANEOUS
Dosage form
INJECTION, SOLUTION
Substance
SEMAGLUTIDE
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GCN Seq No
088775
GCN
58937
HICL code
044675
Ingredient (HICL)
Semaglutide
HIC1 code
J
Therapeutic class — broad (HIC1)
Autonomic Nervous System
HIC2 code
J8
Therapeutic class — intermediate (HIC2)
Anti-Obesity - Anorexics
HIC3 code
J8E
Therapeutic class — specific (HIC3)
Anti-Obesity Glucagon-Like Peptide-1 Recep Agonist
AHFS code
28:20.08.92
AHFS class
Anorexigenic Agents, Miscellaneous
FDB label name
WEGOVY HD 7.2 MG/0.75 ML PEN
FDB brand name
Wegovy Hd
Legend status
F — Federal legend — prescription drug or device
Quick answers
- GSN (GCN sequence number): 088775
- GCN: 58937
- HICL (First Databank): 044675
- AHFS class code: 28:20.08.92
Why two NDCs?
The FDA registers this code as 0169-4572-14 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00169-4572-14. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
Label name WEGOVY HD 7.2 MG/0.75 ML PEN Ingredient Semaglutide
📖 What it is MedlinePlus · NLM
Semaglutide injection is used for the following: to control blood sugar levels in certain patients with type 2 diabetes (condition in which blood sugar is too high because the body does not make or use insulin normally). to reduce the risk of a heart attack, stroke, or death in adults with type 2 diabetes and heart and blood vessel disease. to reduce the risk of a heart attack, stroke, or death in adults who are obese or overweight and have heart and blood vessel disease. to reduce the risk of worsening of kidney disease and death in certain adults with type 2 diabetes and kidney diseas...
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- It depends on the product. Wegovy is used for weight management and to lower heart risks in adults with heart disease plus obesity or overweight. Wegovy injection is also used for...
- Wegovy injection and Ozempic are weekly shots under the skin, any time of day, with or without food. Wegovy tablets are taken once daily on an empty stomach with plain water, then...
- Nausea, diarrhea, vomiting, constipation, and stomach pain are the most common, especially early on or after a dose increase. Headache and tiredness are also common. Call your doct...
- Call for severe stomach pain that won't go away, swelling of the face or throat, trouble breathing, a lump in your neck, trouble swallowing, or hoarseness that persists. Also call...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Semaglutide — tap one for details:
1
Nutrient depletion considerations
Semaglutide may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
💬 Questions about semaglutide?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $434.950 | $1,304.85 / 3 ml |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $664.52 | $1,993.56 / 3 ml |
NADAC price history (per mL) — tap or hover for the price & month
Flat over the last 3 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file · file of Oct 7, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 8, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00169-4572-14 You're viewing this Main listing | 4 SYRINGE, PLASTIC in 1 CARTON / .75 mL in 1 SYRINGE, PLASTIC | 2026-03-19 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Wegovy 7.2 mg/.75mLthis 00169-4572-14 | Novo | 4 syringes | $434.950 | — | Availability likely | — |
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Oct 7, 2026
Availability & generic status
🏛️
2021
First FDA approval
Jun 2021
📍
2026
Currently FDA-listed
5 years listed
🛡️
2041
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.
🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Feb 2041. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
Patents & exclusivity — FDA Orange Book
US 12551536 — method of use (U-4418)
US 12551536 — method of use (U-4418)
US 12214017 — method of use (U-4418)
US 12029779 — method of use (U-4418)
US 11752198 — method of use (U-4418)
US 11318191 — method of use (U-4418)
US 10888605 — method of use (U-4418)
US 9764003 — method of use (U-4418)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 10888605 — method of use (U-3162)
US 9764003 — method of use (U-3161)
US 9764003 — method of use (U-3161)
US 10888605 — method of use (U-3162)
US 9764003 — method of use (U-3161)
US 10888605 — method of use (U-3162)
US 10888605 — method of use (U-3162)
US 9764003 — method of use (U-3161)
US 9764003 — method of use (U-3161)
US 10888605 — method of use (U-3162)
US 12029779 — method of use (U-3162)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-4443)
US 11318191 — method of use (U-4560)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-4443)
US 11318191 — method of use (U-4560)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-4443)
US 11318191 — method of use (U-4560)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-4443)
US 11318191 — method of use (U-4560)
US 11318191 — method of use (U-3162)
US 11318191 — method of use (U-4443)
US 11318191 — method of use (U-4560)
US 12551536 — method of use (U-4418)
US 12029779 — method of use (U-3162)
US 11478533 — method of use (U-3861)
US 9764003 — method of use (U-3161)
US 12569543 — method of use (U-4443)
US 12569543 — method of use (U-4443)
US 12569543 — method of use (U-4443)
US 12569543 — method of use (U-4443)
US 12569543 — method of use (U-4443)
US 12551536 — method of use (U-4418)
US 12551536 — method of use (U-4418)
US 12551536 — method of use (U-4418)
US 12551536 — method of use (U-4418)
US 12551536 — method of use (U-4418)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12214017 — method of use (U-3162)
US 12029779 — method of use (U-3162)
US 12029779 — method of use (U-3162)
US 12029779 — method of use (U-3162)
US 12029779 — method of use (U-3162)
US 12029779 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11752198 — method of use (U-3162)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 11478533 — method of use (U-3861)
US 10888605 — method of use (U-3162)
US 10888605 — method of use (U-3162)
US 10888605 — method of use (U-3162)
US 10888605 — method of use (U-3162)
US 10888605 — method of use (U-3162)
US 9764003 — method of use (U-3161)
US 9764003 — method of use (U-3161)
US 9764003 — method of use (U-3161)
US 9764003 — method of use (U-3161)
US 9764003 — method of use (U-3161)
US 8536122 — drug substance
US 8129343 — drug substance
US 8536122 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
US 8536122 — drug substance
US 8129343 — drug substance
US 8536122 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
US 8536122 — drug substance
US 8129343 — drug substance
US 8129343 — drug substance
Exclusivity I-935
Exclusivity I-973
Exclusivity I-935
Exclusivity I-973
Exclusivity I-935
Exclusivity I-973
Exclusivity D-190
Exclusivity I-935
Exclusivity I-973
Exclusivity I-935
Exclusivity I-973
Exclusivity NS
Exclusivity I-935
Exclusivity I-973
2021
2023
2025
2027
2029
2031
2033
2035
2037
2039
2041
Substance patent
Formulation patent
Method-of-use patent
Exclusivity
Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
Listed patents (115)
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12214017 ↗ | Method of use | U-4418 | Aug 24, 2038 |
| US 12029779 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 11752198 ↗ | Method of use | U-4418 | Aug 24, 2038 |
| US 11318191 ↗ | Method of use | U-4418 | Feb 17, 2041 |
| US 10888605 ↗ | Method of use | U-4418 | Aug 24, 2038 |
| US 9764003 ↗ | Method of use | U-4418 | Jun 21, 2033 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4443 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4560 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4443 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4560 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4443 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4560 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4443 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4560 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-3162 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4443 | Feb 17, 2041 |
| US 11318191 ↗ | Method of use | U-4560 | Feb 17, 2041 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 12569543 ↗ | Method of use | U-4443 | Apr 28, 2037 |
| US 12569543 ↗ | Method of use | U-4443 | Apr 28, 2037 |
| US 12569543 ↗ | Method of use | U-4443 | Apr 28, 2037 |
| US 12569543 ↗ | Method of use | U-4443 | Apr 28, 2037 |
| US 12569543 ↗ | Method of use | U-4443 | Apr 28, 2037 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12551536 ↗ | Method of use | U-4418 | Oct 10, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12214017 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 12029779 ↗ | Method of use | U-3162 | Oct 10, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11752198 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 11478533 ↗ | Method of use | U-3861 | May 13, 2040 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 10888605 ↗ | Method of use | U-3162 | Aug 24, 2038 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 9764003 ↗ | Method of use | U-3161 | Jun 21, 2033 |
| US 8536122 ↗ | Drug substance | — | Mar 20, 2026 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8536122 ↗ | Drug substance | — | Mar 20, 2026 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8536122 ↗ | Drug substance | — | Mar 20, 2026 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8536122 ↗ | Drug substance | — | Mar 20, 2026 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8536122 ↗ | Drug substance | — | Mar 20, 2026 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
| US 8129343 ↗ | Drug substance | — | Dec 5, 2031 |
FDA exclusivity
| Code | What it grants | Expires |
|---|---|---|
| I-935 | New indication (3-year) | Mar 8, 2027 |
| I-973 | New indication (3-year) | Aug 15, 2028 |
| I-935 | New indication (3-year) | Mar 8, 2027 |
| I-973 | New indication (3-year) | Aug 15, 2028 |
| I-935 | New indication (3-year) | Mar 8, 2027 |
| I-973 | New indication (3-year) | Aug 15, 2028 |
| D-190 | Other change requiring clinical data (3-year) | Jul 21, 2026 |
| I-935 | New indication (3-year) | Mar 8, 2027 |
| I-973 | New indication (3-year) | Aug 15, 2028 |
| I-935 | New indication (3-year) | Mar 8, 2027 |
| I-973 | New indication (3-year) | Aug 15, 2028 |
| NS | New Strength | Mar 19, 2029 |
| I-935 | New indication (3-year) | Mar 8, 2027 |
| I-973 | New indication (3-year) | Aug 15, 2028 |
Common questions
Is there a generic version of WEGOVY HD 7.2 MG/0.75 ML PEN?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for WEGOVY HD 7.2 MG/0.75 ML PEN. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Feb 2041 — an estimate, not a guaranteed launch date.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Color
White
ShapeOval
Imprint25;novo
Size12 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Semaglutide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 94255I6E2T
Sodium phosphate dibasic dihydrate is a salt that helps control the acidity level of a medicine. It acts as a buffer and pH regulator to keep the medication stable and effective.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerNovo Nordisk Pharmaceutical Industries, LP
Application holderNOVO NORDISK INC
FDA applicationNDA215256 (NDA)
Labeler code00169
First marketedJun 2021
Product typeHuman Prescription Drug
Portfolio39 products on file
More NDCs from Novo Nordisk Pharmaceutical Industries, LP labeler code 00169
- Wegovy semaglutide 25 mg Tablet NDC 0169-4425-31
- WEGOVY semaglutide 1 mg/.5mL Injection, Solution NDC 0169-4501-14
- WEGOVY semaglutide .5 mg/.5mL Injection, Solution NDC 0169-4505-14
- WEGOVY semaglutide 1.7 mg/.75mL Injection, Solution NDC 0169-4517-14
- WEGOVY semaglutide 2.4 mg/.75mL Injection, Solution NDC 0169-4524-14
- WEGOVY semaglutide .25 mg/.5mL Injection, Solution NDC 0169-4525-14
- Ozempic semaglutide 2.68 mg/mL Injection, Solution NDC 0169-4772-12
- Vagifem estradiol 10 ug Insert NDC 0169-5176-03
- RIVFLOZA nedosiran 160 mg/mL Injection, Solution NDC 0169-5306-10
- RIVFLOZA nedosiran 128 mg/.8mL Injection, Solution NDC 0169-5307-08
- RIVFLOZA nedosiran 80 mg/.5mL Injection, Solution NDC 0169-5308-01
- NOVOLOG insulin aspart 100 [iU]/mL Injection, Solution NDC 0169-6339-10
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Wegovy — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Wegovy. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$297.5M
Claims incl. refills
205.6K
Beneficiaries
88.8K
Spend / beneficiary
$3,352.12
Spend / claim
$1,446.68
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Semaglutide — the ingredient across all brands.
Top reported reactions
Reporter sex
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.